1. Barlow RB. Effects of "rogue" points on non-linear fitting. TIPS 1993;14:399–403.

2. Birkett DJ, MacKenzie PI, Veronese ME, Miners JO. In vitro approaches can predict human drug metabolism. TIPS 1993;14:292–294.

3. Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18: 220–239.

4. Browne TR. Stable isotopes in clinical pharmacokinetic investigations. Advantages and disadvantages. Clin Pharmacokinet 1990; 18:423–433.

5. Browne TR. Stable isotopes in pharmacology studies: present and future. J Clin Pharmacol 1986;26:485–489.

6. Browne TR, Szabo GK. New pharmacokinetic methods for the study of antiepileptic medications of the 1990s. Epilepsia 1991; 32[Suppl 5]:S66–S73.

7. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. TIPS 1992;13:434–439.

8. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions. J Clin Psychopharmacol 1990;10:48–50, 213–217.

9. Colburn WA. Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharmaceut 1981;9:367–388.

10. Dingemanse J, Danhof M, Breimer DD. Pharmacokinetic–pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther 1988;38:1–52.

11. Friedman H, Greenblatt DJ. Rational therapeutic drug monitoring. JAMA 1986;256:2227–2233.

12. Friedman H, Greenblatt DJ, Peters GR, et al. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol Ther 1992;52:139–150.

13. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1975.

14. Gonzalez FJ. Human cytochromes P450. TIPS 1992;13:346–352.

15. Gonzalez FJ. In vitro systems for prediction of rates of drug clearance and drug interactions. Anesthesiology 1992;77:413–415.

16. Goodchild CS. GABA receptors and benzodiazepines. Br J Anaesth 1993;71:127–133.

17. Greenblatt DJ, Harmatz JS. Kinetic-dynamic modeling in clinical psychopharmacology. J Clin Psychopharmacol 1993;13:231–234.

18. Greenblatt DJ, Koch-Weser J. Clinical pharmacokinetics. N Engl J Med 1975;293:702–705, 964–970.

19. Greenblatt DJ, Sethy VH. Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam. Psychopharmacology 1990;102:373–378.

20. Greenblatt DJ, Shader RI. Pharmacokinetics in clinical practice. Philadelphia: WB Saunders; 1985.

21. Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin Pharmacol Ther 1989;45:356–365.

22. Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J Pharmacol Exp Ther 1989;250:134–140.

23. Greenblatt DJ, Harmatz JS, Gouthro TA, Locke J, Shader RI. Distinguishing a benzodiazepine agonist (triazolam) from a non-agonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther 1994;56:110–111.

24. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations. Clin Pharmacokinet 1991;21:165–177, 262–273.

25. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691–1698.

26. Guengerich FP. Bioactivation and detoxication of toxic and carcinogenic chemicals. Drug Metab Disp 1993;21:1–6.

27. Guengerich FP. Human cytochrome P-450 enzymes. Life Sci 1992;50:1471–1478.

28. Haefely WE. The GABAA-benzodiazepine receptor: biology and pharmacology. In: Burrows GD, Roth M, Noyes Jr R, eds. Handbook of Anxiety, Vol 3, The Neurobiology of Anxiety. Amsterdam: Elsevier; 1990:165–188.

29. Harmatz JS, Greenblatt DJ. A SIMPLEX procedure for fitting nonlinear pharmacokinetic models. Comp Biol Med 1987;17:199–208.

30. Holford NHG, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982;16:143–166.

31. Hommer DW, Matsuo V, Wolkowitz O, et al. Benzodiazepine sensitivity in normal human subjects. Arch Gen Psychiatry 1986;43: 542–551.

32. Mandema JW, Danhof M. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet 1992;23:191–195.

33. Motulsky HJ, Ransnas LA. Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J 1987;1:365–374.

34. Murray M. P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992;23:132–146.

35. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90–98.

36. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979;25:358–371.

37. Stanski DR. Pharmacodynamic modeling of anesthetic EEG drug effects. Annu Rev Pharmacol Toxicol 1992;32:423–447.

38. Szabo GK, Browne TR. Mass spectrometry: preparation of biologic specimens. J Clin Pharmacol 1986;26:400–405.

39. van Steveninck AL, Mandema JW, Tuk B, et al. A comparison of the concentration-effect relationships of midazolam for EEGderived parameters and saccadic peak velocity. Br J Clin Pharmacol 1993;36:109–115.

40. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278–1283.

41. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993;47:268–276.

42. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Cytochromes in psychopharmacology. J Clin Psychopharmacol 1994; 14:1–4.

43. Wagner JG. Fundamentals of clinical pharmacokinetics. Hamilton, IL: Drug Intelligence Publications; 1975.